Annexin is currently in the process of a rights issue, the subscription period of which runs until Friday, February 21, to raise SEK 61 million before issue costs. The company plans to use the proceeds to take the next step in the development work with ANXV and plans to initiate clinical phase I during the year. Hear CEO Anders Haegerstrand tell you more about the issue and the potential market for ANXV in the interview below.
Se Annexin Pharmaceuticals vd Anders Haegerstrand present the company and the share offering below.
Also hear Anders Haegerstrand tell more about the issue and the potential market for ANXV in the interview below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
|
Published February 17, 2020
BioStock Live: Issue-related Annexin aims for clinical trials in 2020
Last Thursday it was time for the first BioStock Live of the year and one of the companies participating was Stockholm-based Annexin Pharmaceuticals. The company is developing the candidate ANXV which is intended for the acute treatment of patients with various types of vascular diseases, with a focus on retinal vein occlusion.